Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

ZO-1 is a high molecular mass phosphoprotein peripherally associated with the cytoplasmic surface of tight junctions in epithelial and endothelial cells. We report here that ZO-1 is also present in several nonepithelial cell types in vitro that are not believed to form tight junctions, including primary cultures of astrocytes, Schwann cells, and dermal fibroblasts and the C6 glioma, S-180 (sarcoma), and P3 myeloma cell lines. Immunoblots of cell extracts probed with a ZO-1-specific monoclonal antibody reveal a single band that comigrates with ZO-1 from rodent epithelial cells at 225 kDa. In addition, these cells contain a single mRNA species of identical size to that previously reported for ZO-1 in epithelial tissues, as determined by Northern blots probed with a partial ZO-1 cDNA. Immunofluorescence microscopy demonstrates diverse ZO-1 distributions in these cells. In astrocytes, identified by the presence of glial fibrillary acidic protein, ZO-1 is localized at discrete sites of cell-cell contact as well as within the cell cytoplasm. In contrast, S-180 cells display diffuse staining at the cell periphery and within the cytoplasm. Dermal fibroblasts show no staining above background, although ZO-1 was detected on immunoblots of fibroblast cell extracts. Immunofluorescence staining of frozen sections of mouse brain demonstrates no detectable ZO-1 immunoreactivity outside blood vessels where endothelial cell tight junctions of the blood-brain barrier are located. These studies suggest that, although ZO-1 is found to be associated with the tight junction, it has a broader distribution than previously recognized.
 ...
PMID:Detection of the tight junction-associated protein ZO-1 in astrocytes and other nonepithelial cell types. 153 34

The Hodgkin-associated Ki-1 antigen (CD30) consists of a 120-kDa membrane-associated glycosylated phosphoprotein (Ki-1/120) and a 57-kDa non-glycosylated phosphoprotein (Ki-1/57) which only occurs intracellularly. Both molecules are phosphorylated at serine residues. An analysis of the peptide fragments resulting from staphylococcal V8-protease digestion of the Ki-1/57 molecule revealed identical bands irrespective of the cell source. Only a few bands of the Ki-1/57 digests appeared among the peptide fragments of the Ki-1/120 membrane antigen. The protein kinase activity was tested for both forms of the Ki-1 antigen. The Ki-1/120, devoid of the Ki-1/57 molecule, was immunoprecipitated from cell lysates of Hodgkin-analogous cell lines L428 or L540, which had been loaded with the Ki-1 or the Ki-1-analogous antibodies Ber-H2, HSR-1, -2 and -3 (method 1). These other antibodies reacted with the Ki-1/120, but not with the Ki-1/57 antigen. The latter, devoid of the Ki-1/120, was isolated from L540 cells after removal of the membrane form by method 1 or from U266/Bl myeloma or Raji Burkitt lymphoma cells which only contain the smaller form. Effects of non-specific adsorption were eliminated by various control precipitates. The Ki-1/57 intracellular antigen showed autophosphorylation and could phosphorylate histones as well. In contrast, a protein kinase activity of the membrane-associated Ki-1/120 could not be demonstrated.
 ...
PMID:Protein kinase activity of the intracellular but not of the membrane-associated form of the Ki-1 antigen (CD30). 216 Nov 15

The lymphocytes from lymph nodes of six patients with metastatic mammary carcinomas were hybridised by fusion with a non-secreting variant of murine myeloma cells. Hybrid cells producing human immunoglobulin were detected by screening of culture supernatants using a solid-phase enzyme-linked immunosorbent assay for human IgG or IgM. Reactivity of human immunoglobulins to breast tumour cells was assessed by an indirect immunoperoxidase staining of fresh-frozen breast carcinoma sections. In the initial screening, the tissues used were those removed from the patients who acted as source of lymphocytes for fusion. The hybrid-cells, after repeated cloning, were stable for secretion of immunoglobulins. A total of 14 immunoglobulin G and 51 immunoglobulin M human monoclonal antibodies, showing variable reactivity to mammary carcinoma cells in tissue sections by an indirect immunoperoxidase staining method, were obtained. Two immunoglobulin G monoclonal antibodies (designated HMA-29 and HMA-31) were selected on the basis of their strong reactivity to the tumour cells and utilised to identify their corresponding antigens. The antibodies quantitatively discriminated, as expressed by the degree of staining, malignant from normal or benign mammary epithelia in freshly frozen or formalin-fixed breast tissues. The antibodies also showed reactivity to malignant cells of colon, stomach and lung and to normal cells lining the renal tubules and surface epithelium of colon. As revealed by blocking experiments, the epitopes recognised by these antibodies were not expressed on carcinoembryonic antigens, erythrocytes, lymphocytes, glycoproteins from milk-fat-globule membrane or keratins. The antibody HMA-29 immunoprecipitated a phosphoprotein (Mr = 29,000), and antibody HMA-31 two protein components (Mr = 31,000 and 34,000), from lysates of intrinsically labelled human mammary carcinoma cell line (MCF7). Neither of these proteins were present in detectable amounts in an intrinsically labelled melanoma cell line. Immunoblocking and immunoprecipitation experiments suggested that epitopes recognised by these two antibodies are dissimilar and are expressed on different molecules. The antibodies appear to be useful for functional characterisation of those antigens which are present in elevated levels in malignant compared with normal mammary epithelia.
 ...
PMID:Biochemical and immunological characterizations of antigens recognised by human monoclonal antibodies. 247 67

The monoclonal antibody to the epidermal growth factor (EGF) receptor was generated after fusion of PAI myeloma cells with immunized BALB/c mouse spleen cells, using intact A431 epidermoid carcinoma cells as an immunogen. The antibody, denoted 5A9, is an IgG, which recognizes a protein with molecular mass 170 kDa during immunoblot analysis, immunoprecipitates phosphoprotein with molecular mass 170 kDa from the membrane preparations of A431 cells, and, according to immunofluorescence experiments, is distributed in the cell similar to the EGF-rhodamine conjugate. It is concluded that the produced antibodies are specific to EGF-receptor. At the same time the 5A9 (50 nM) do not compete with EGF for binding with high and low affinity receptors. They fail to induce internalization of the EGF-receptor and do not exert influence on intracellular degradation of EGF-receptor. Monoclonal antibodies 5A9 are also unable to inhibit the EGF-induced protein kinase activity of the receptor and do not stimulate protein kinase activity by themselves. Thus, the prepared monoclonal antibodies can be used to register the EGF-receptor cellular localization without affecting biologic activity of the receptor.
 ...
PMID:[Isolation and characteristics of monoclonal antibodies to the external domain of the EGF receptor in human A431 epidermoid carcinoma]. 247 49

The Hodgkin-associated Ki-1 antigen occurs in two different molecular forms. The 120-kDa membrane-associated form is a phosphorylated glycoprotein, which is derived from a non-phosphorylated intracellular 84-kDa apoprotein that is co-translationally N-glycosylated with a carbohydrate portion of 6 kDa. The other form of the Ki-1 antigen is a non-glycosylated phosphoprotein of 57 kDa which only occurs intracellularly. Both forms of the antigen are phosphorylated at serine residues. Enzymatic cleavage with sialidase reduced the 120-kDa membrane antigen by about 15 kDa, while its 90-kDa precursor and the 57-kDa intracellular form of the Ki-1 antigen remained unaltered. Pulse-chase experiments revealed that the 57-kDa and 90/120-kDa molecules are synthesized independently of each other. Four to eight hours after synthesis, the degradation of the 120-kDa molecule to a 105-kDa membrane-associated intermediate begins. This is further processed and appears in the cell supernate as a 90-kDa molecule. Hodgkin's disease-derived, Epstein-Barr virus-transformed cell lines and the acute T cell leukemia line MOLT-4 contain both forms of the Ki-1 antigen, whereas only the 57-kDa intracellular antigen is expressed in U266/B1 myeloma cells, in the Burkitt lymphoma cell lines Raji and Daudi and in acute promyelocytic HL-60 leukemia cells.
 ...
PMID:The Hodgkin-associated Ki-1 antigen exists in an intracellular and a membrane-bound form. 254 29

Monoclonal and polyclonal antibodies were raised against 150k, 60k, 32k, and 15k phosphoprotein components of 14-week chicken bone. Hybridomas were prepared by immunizing Balb/c mice with 150k, 60k, or 32k phosphoproteins followed by fusion of their spleen cells with X63-Ag8.653 myeloma cells. Polyclonal antibodies to the 60k, 32k, and 15k phosphoprotein components were produced in immunized rabbits. Immunological cross-reactivity between antigen and antibody was examined by enzyme-linked immunosorbent assay (ELISA) and dot-blotting. There was cross-reactivity between the 150k, 32k, and 15k phosphoprotein components and between the 150k, 90k, and 60k components. The antibodies raised against 60k component do not bind 32k and 15k antigens.
 ...
PMID:Preparation of monoclonal antibodies to chicken bone phosphoproteins. 314 19

A monoclonal antibody was raised against phosphophoryn, a unique noncollagenous phosphoprotein in dentin. Mouse myeloma NS-I cells were fused with spleen cells obtained from BALB/c mice immunized with phosphophoryn from fetal calf tooth germs. Mice inoculated with the hybridoma produced ascites fluid containing the antibody and this reacted only with a band of phosphophoryn transblotted from polyacrylamide gel. Immunohistochemical studies with the antibody showed that phosphophoryn was present in odontoblasts, odontoblastic processes and dentin, but not in the matrix of predentin, and that the phosphophoryn content of the dentin layer was high at and around the predentin-dentin junction and gradually decreased toward the enamel layer. The area corresponding to mantle dentin was not stained with the antibody.
 ...
PMID:Immunohistochemical studies with a monoclonal antibody on the distribution of phosphophoryn in predentin and dentin. 393 88

An improved screening procedure was applied to identify hybridomas secreting antibodies to herpesvirus saimiri-specified polypeptides among the products of fusions between SP2/0 myeloma cells and spleen cells from mice immunized with purified virus particles or virus-specific DNA-binding proteins. Twenty-four monoclonal antibodies were isolated with specificities for 13 different virus-specified polypeptides (or complexes of polypeptides), including the major capsid protein of the virus (150K), the 160K and 130K structural proteins, a 108K structural phosphoprotein, structural glycoproteins, the nonstructural early 76K protein, early nonstructural DNA-binding proteins of 48 to 51K and 110K and the major immediate-early protein of 52K. Antibody to the virus 76K protein precipitated a host protein of 62K, and a number of antibodies specific for host proteins were also isolated. Antibody to the 52K immediate-early polypeptide precipitated the delayed-early 76K protein, whereas the antibody to the 76K protein did not precipitate the 52K polypeptide. These observations suggest the presence of epitopes common to virus and host proteins and an antigenic site common to an immediate-early and a delayed-early virus protein. The antibodies were used to examine the sites of intracellular accumulation of virus polypeptides, the formation of complexes of structural proteins, and the postsynthetic processing of virus proteins. The present collection of monoclonal antibodies provides a set of reagents with specificities for members of each of the major kinetically or functionally distinct classes of virus gene products.
 ...
PMID:Isolation and characterization of monoclonal antibodies to structural and nonstructural herpesvirus saimiri proteins. 609 17

Five hybridoma cell lines secreting monoclonal antibodies (MAbs) to a 65-kDa tumor-associated phosphoprotein (p65) were established. Purified to homogeneity, p65 was used as an immunogen to induce immune response in C57BL/6N mice. Splenocytes were fused with mouse myeloma cells and hybridoma lines were selectively subcloned. A rapid and sensitive sandwich type ELISA, using purified MAbs was established to measure markedly elevated amounts of p65 in sera obtained from both tumor-bearing rats and from cancer patients. The p65 from rat and human sources was added quantitatively to normal sera to construct standard curves. The average level of p65 in normal rat sera was 38 ng/ml +/- 13 ng/ml (mean +/- SD), and in sera from rats bearing mammary adenocarcinomas, the average value was 1005 +/- 140 ng/ml. In normal human sera the mean level of p65 was 34 +/- 35 ng/ml (mean +/- SD) and sera of patients with variety of cancers had an average p65 value of 344 +/- 57 ng/ml. More than 80% of tested sera from adenocarcinoma-bearing rats (20/24) as well as from cancer patients (82/98) had p65 levels elevated two standard deviations above the mean. Overall the assay had a sensitivity of 80.9% and specificity of 85%. The purified IgG1 MAbs, with high titers and strong anti p65 specificities were also used to develop an immunohistochemical method to visualize the expression of p65 in rat tumor tissue sections. The HB2, HF11 and RE6 cell lines have proved to be quite stable in the ability to secrete anti-p65 MAbs.
 ...
PMID:Monoclonal antibodies against a 65-kDa tumor-associated phosphoprotein: development and use in cancer detection. 831 97

Hematopoietic malignancies have been shown to depend on cytokine growth factor autocrine/paracrine loops for growth and differentiation. This results in the constitutive activation of cytokine-mediated transcription factors like signal transducer and activators of transcription (STAT) 3 in non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Recent evidence demonstrates that cytokines also contribute to a drug-resistant phenotype in many tumor cell types. We hypothesized that inhibitors of the STAT3 pathway would sensitize drug-resistant and endogenous cytokine-dependent NHL and MM tumor cells to the cytotoxic effects of chemotherapeutic drugs. We examined an AIDS-related NHL cell line, 2F7, known to be dependent on interleukin (IL)-10 for survival and an MM cell line, U266, known to be dependent on IL-6 for survival. IL-10 and IL-6 signal the cells through the activation of Janus kinase (JAK)1 and JAK2, respectively. Thus, we investigated the effect of two chemical STAT3 pathway inhibitors, namely, piceatannol (JAK1/STAT3 inhibitor) and tyrphostin AG490 (JAK2/STAT3 inhibitor), on the tumor cells for sensitization to therapeutic drugs. We demonstrate by phosphoprotein immunoblotting analysis and electrophoretic mobility shift analysis that piceatannol and AG490 inhibit the constitutive activity of STAT3 in 2F7 and U266, respectively. Furthermore, piceatannol and AG490 sensitize 2F7 and U266 cells, respectively, to apoptosis by a range of therapeutic drugs including cisplatin, fludarabine, Adriamycin, and vinblastine. The specificity of the inhibitors was corroborated in experiments showing that piceatannol had no effect on U266 and, likewise, AG490 has no effect on 2F7. The sensitization observed by these inhibitors correlated with the inhibition of Bcl-2 expression in 2F7 and Bcl-xL expression in U266. Altogether, these results demonstrate that STAT3 pathway inhibitors are a novel class of chemotherapeutic sensitizing agents capable of reversing the drug-resistant phenotype of cytokine-dependent tumor cells.
 ...
PMID:Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. 1253 84


1 2 Next >>